Professional antigen-presenting cells (APCs), such as DCs, process and present tumour antigens in complex with major histocompatibility class I and II molecules (MHC-I or MHC-II) for the stimulation of CD8 and CD4 T cells through TCR-mediated recognition [4]. The gene discussed is CD8A; the disease is neoplasm.